Magazine: Smart and connected packaging
With the recent conclusion of PharmaPack 2026, this month’s magazine is focused on the key messaging that emanated from the event. With the …
Post
-
-
Lumosa’s stroke drug shows potential on double Phase II win
Lumosa Therapeutics has posted positive results from two independent Phase II clinical trials of its lead asset, odatroltide (LT3001) in …
-
SLE: four trials to watch in 2026
As Spring edges closer, rheumatology experts are preparing for The European Lupus Society’s 15th Annual European Lupus Meeting, which will …
-
FDA approves PharmaResearch IND application for PRD-101 trial
The US Food and Drug Administration (FDA) has granted clearance for PharmaResearch’s PRD-101 investigational new drug (IND) application, enabling the …
-
Genentech reports fenebrutinib Phase III results for PPMS
Roche’s Genentech has reported new data from the Phase III FENtrepid trial of fenebrutinib, an investigational Bruton’s tyrosine kinase inhibitor, …
-
UniQure pauses dosing in Fabry disease trial amid safety concerns
UniQure has ceased dosing in two cohorts in a Phase I/IIa trial of its adeno-associated viral (AAV) gene therapy, AMT-191, …
-
WHO analysis shows four in ten cancers could be prevented
Globally, cancer is a leading cause of death and presents a significant challenge to public health. Despite major therapeutic advances …
-
£1bn London Cancer Hub extension gets go-ahead amid UK life sciences push
The London Cancer Hub, a key centre for the UK’s oncology research output, is undergoing a major expansion to increase …
-
Bayer’s Factor XIa inhibitor reduces repeat stroke risk by 26% in pivotal trial
Bayer’s investigational, once-daily, oral Factor XIa inhibitor asundexian reduced the risk of recurrent ischemic stroke by 26% in a pivotal …
-
Aicuris reports positive Phase III pritelivir results for HSV patients
Aicuris has reported positive findings from its pivotal Phase III trial (PRIOH-I) assessing pritelivir in immunocompromised patients with refractory herpes …
-
TransCode and Quantum Leap seek FDA approval for Phase IIa TTX-MC138 trial
A partnership comprising TransCode Therapeutics and Quantum Leap Healthcare Collaborative has submitted an investigational new drug (IND) application amendment seeking …
-
Lilly stops development of three drugs, including gene therapy
Eli Lilly is dropping the development of three therapies that did not meet expectations, including a gene therapy acquired during …
-
DiMe unveils sDHT Adoption Navigator to advance clinical trial integration
The Digital Health Measurement Collaborative Community (DATAcc) by the Digital Medicine Society (DiMe) has introduced the sDHT Adoption Navigator, an …
-
J.P. Morgan Healthcare Conference 2026 Report
The J. P. Morgan Healthcare Conference 2026 (JPM 2026) offers an early view of investor sentiment in the healthcare industry …
-
Affinia receives FDA approval for Phase I/II trial for dilated cardiomyopathy
Affinia Therapeutics has received approval from the US Food and Drug Administration (FDA) for an investigational new drug (IND) application …
